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Unlike other soft tissue sarcomas, myxoid/round cell liposarcoma (MRCL) has a tendency to spread to extrapulmonary sites
but bone metastases are thought to be uncommon. In case reports, negative bone scintigraphy has been noted in patients with
myxoid/round cell liposarcoma and bone metastases but the prevalence and optimal method of diagnosis of bone metastases in
this common subtype of liposarcoma are unclear. In an attempt to answer these questions, data were obtained from a prospective
database of patients with sarcoma, including MRCL, and the diagnostic imaging used was examined. A variety of imaging tools
were used including plain X-rays, bone scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI). Eight
patients (4.3%) developed skeletal metastases all of which were positive on MRI. Bone scintigraphy was negative in two out of four
cases, CT was negative in six out of seven, and X-rays were negative in four. Radiography and CT measure mainly cortical bone
involvement, whereas MRI examines bone marrow. When investigating patients with MRCL for bone pain, negative X-rays and
bone scans do not rule out bone metastases. In our experience, MRI provides the most sensitive technique for the diagnosis of
bone metastases in MRCL.
1.Introduction
Liposarcoma is one of the most common histologic types of
soft tissue sarcoma. There are several subtypes of liposar-
coma, of which myxoid liposarcoma represents about one
third of cases [1]. Myxoid/round cell liposarcoma (MRCL)
is associated with an unusual pattern of spread in that
it has a predilection for extrapulmonary sites such as
retroperitoneum, mediastinum, and other soft tissue sites
[2–4]. The degree to which MRCL metastasizes to bone is
not clear but the incidence in one series has been reported
to be 17%, comprising 56% of all metastatic events [5].
Isolatedcasereportshavealsoreportedthisphenomenon[6–
8]. Screening for suspected bone metastases has classically
been performed using bone scintigraphy but this may be
inaccurate in tumours such as myeloma and renal cancer,
in which conventional scintigraphy is inferior to plain X-
ray [9, 10]. Following reports that bone scintigraphy also
underdiagnoses metastatic bone disease in the case of MRCL
[5, 6, 8], we performed this retrospective study to examine
the prevalence of known bone metastases in our patient
population and report our experience of diagnostic imaging
with MRCL.
2.MaterialsandMethods
Patients with a diagnosis of myxoid/round cell liposarcoma
were identiﬁed from the prospective soft tissue sarcoma
database. Between 1974 and 2006, 184 patients were diag-
nosed and treated. Well-diﬀerentiated, dediﬀerentiated, and
pleomorphic liposarcomas were excluded. The diagnosis of
MRCL was conﬁrmed by a review of the histology in all cases
at presentation. The diagnosis of MRCL was based on the
presence of uniform round to oval shaped cells in a myxoid
background, associated with a plexiform capillary network.
Because of the lack of necrosis and minimal tumour cell
pleomorphism, factors key to the grading of the majority of
soft tissue sarcomas, grading in MRCL are instead based on
the cellularity of the tumour and speciﬁcally the percentage
of round cells noted on all individual sections. A two-
tiered grading system has typically been employed where
tumours with >5% round cells are considered high grade,2 Sarcoma
and those with <5% round cells are considered low grade
[3].
The medical records of all 184 patients with MRCL,
including follow-up appointments, were reviewed. The
reports of all imaging including plain X-rays, bone scintig-
raphy, computed tomography (CT), magnetic resonance
imaging (MRI), and positron emission tomography (PET)
were reviewed. All patients were followed up clinically with
CT or chest X-ray surveillance for metastasis. The CT
technique used was a conventional spiral scan for thorax
abdomen and pelvis. If spinal disease was suspected or
nerve root pain was being investigated, MRI was performed.
Local recurrence was monitored by physical examination.
Additional screening tests were requested if other sites of
metastasis were suspected.
For the 8 patients identiﬁed with skeletal metastases,
the actual imaging was reviewed where available. For the
majority of spinal examinations, imaging was requested to
investigatepain.Allpatientswithsuspectedspinalmetastases
had a whole-spine MRI scan with T1- and T2- weighted
sequences in the axial and sagittal planes. Where bone
marrow abnormalities were observed on imaging but there
was doubt concerning the existence of metastatic disease, a
b i o p s yw a sp e r f o r m e da n do t h e rd i a g n o s e s ,s u c ha sm u l t i p l e
myeloma, were excluded by standard tests such as bone
marrow biopsy and plasma immunoglobulin studies. Some,
but not all, patients had bone scintigraphy and one patient
had an FDG-PET scan.
3. Results
184 patients with a diagnosis of MRCL were identiﬁed from
our prospective sarcoma database (Table 1). Eight (4.3%)
of the 184 patients with MRCL were diagnosed with bone
metastases, four of whom presented with back pain while the
rest were discovered on routine imaging or investigation of
tumour masses. In one patient, a spinal MRI was performed
to investigate resectability of a paraspinal tumour, one
patient had MRI of the trunk for ease of comparison with
previous imaging and one patient with known abdominal
disease had a deposit at L2 identiﬁed on an MRI. The spine
was the ﬁrst known site of metastasis in seven patients. Other
sites of bone metastasis included sternum, femur, skull, and
ribs. Four of the eight patients had bone scintigraphy which
failed to demonstrate bone metastases in two cases and was
equivocal in another. Seven of the eight patients had relevant
CT scans of which six were negative for bone involvement
andfourpatients had plain X-rays,allofwhich werenegative
for bone metastases. One patient underwent a PET scan
which was negative for spinal metastases but only showed
low-grade uptake in the primary tumour, hence the negative
result is of uncertain signiﬁcance.
These ﬁndings are illustrated by the following examples.
Patient 1 was diagnosed with MRCL in a paravertebral
muscle which was excised with a marginal excision. He
relapsed locally one year later and at this time an MRI scan
showed tumour in the L2 vertebral body (Figure 1). Low
signalwasseenwithinthebodyofL2onT1correspondingto
high signal on T2 in keeping with an intraosseous metastasis.
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Figure 1: The MRI scan shows homogeneous isointense signal
relative to skeletal muscle on T1-weighted images throughout L2
vertebra. The cortex is intact.
A staging CT scan was performed showing no signiﬁcant
abnormality on bone windows at L2 or elsewhere (Figure 2).
Plain X-rays and bone scan were not performed. The patient
went on to receive chemotherapy with a good response but
has since progressed.
Patient 2 ﬁrst presented in 1992 with MRCL in the
left thigh which was excised. He relapsed locally on two
occasions, treated by local excision. In 2005, during MRI
staging for liver metastasectomy, multiple bone metastases
were seen throughout the cervical, thoracic, lumbar spine,
and sacrum (Figure 3). There was no evidence of cord
compression. The patient was asymptomatic at the time.
A bone scan, at this time, was negative for metastatic
disease (Figure 4). The skeletal survey showed no lytic
lesions and the CT also showed no evidence of tumour in
the spine (Figure 5). The patient subsequently underwent
chemotherapy and radiotherapy to sites of painful metastatic
bone disease and died two years later.
4. Discussion
Liposarcoma is one of the commonest subtypes of soft
tissue sarcoma constituting 9.8–18% of cases [1, 11]. The
incidence peaks between 40 and 60 years and there is a
slight male predominance [1]. The World Health Orga-
nization recognizes four subtypes: well-diﬀerentiated, de-
diﬀerentiated, myxoid/round cell, and pleomorphic. The
myxoid/round cell subtype is among the most prevalent and
typically occurs in younger individuals with a peak in the
4th and 5th decades [12]. In contrast to other soft tissue
sarcomas which tend to metastasize to the lung, liposarcoma
has a propensity to spread to extrapulmonary sites [13, 14].Sarcoma 3
Table 1
Age at
diagnosis
Gender Tumour
grade∗
Time to bone
disease (yrs)
Sites of bone
disease on MRI
CT# X-ray# Scintigraphy# Other sites of disease
28 Male low 5 Lumbar spine,
sacrum
ND ND Neg Soft tissue pelvis
44 Male low 5.25 Spine, pelvis Neg Neg Neg Lungs
29 Male High 0.6 Spine, skull,
femur
Neg Neg Pos Soft tissue abdomen
30 Female High 6 Spine Neg ND ND Pleura
42 Male High 11 Sternum, ilium Pos sternum ND ND Lung, soft tissue
34 Female low 2.5 Dorsal spine Neg Neg Equivoca Abdo, multiple soft tissue
45 Male High 0.75 Lumbar spine Neg ND ND Pleura, abdomen
72 Male low 7.75 Dorsal spine Neg Neg Neg Paraspinal soft tissue
∗<5% round cells = low grade, >5% = high grade.
#N D= not done.
Pos = conﬁrmatory.
Neg = not conﬁrmatory.
·+1(2) 1
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Figure 2: There is a right-sided paraspinal metastatic lesion. The bone windows on CT scan show very subtle lytic change in the vertebral
body of L2 which was not considered signiﬁcant at the time of reporting.
MRCL in particular tends to spread to other soft tissue sites
including retroperitoneum, thorax, opposite extremity and
other soft tissue sites before metastasizing to the lungs [2–4].
SkeletalmetastaseshavealsorecentlybeenreportedinMRCL
but the prevalence is unclear [12].
We identiﬁed 8 patients with skeletal metastases on
radiographic criteria in a population of 184 patients with
MRCL, that is, an incidence of 4.3%. Of these patients,
metastatic bone disease was proven at spinal surgery in one
case, thought likely on bone marrow aspiration cytology in
one, and in one case was evident both clinically and on
imaging in that the bone metastasis evolved into a large bone
and soft tissue mass. The other patients all had other sites
of metastatic disease at the time of diagnosis of metastatic
bone disease. This is likely to be an underestimate of the
trueincidenceofmetastaticbonedisease,sincebonemarrow
involvement, in particular spinal metastases, can initially be
a s y m p t o m a t i c ,a sw ef o u n d .T h e r eh a v eb e e ns e v e r a lr e p o r t s
of the unreliability of various modes of imaging of bone
metastases in MRCL. One of our cases has previously been
reported emphasising the fact that the bone disease was
only detectable by MRI [15]. Ishii et al. reported two cases
of skeletal metastases from MRCL, both were undetectable
using plain X-rays and bone scans but were detectable on
MRI [6]. Similarly, Sheah et al., reported 12 patients with
metastatic MRCL who were examined using CT, MRI, and
PET [16]. CT showed mixed lytic and sclerotic foci, with
bone destruction in advanced cases. MRI demonstrated
ﬂuid-like signal intensity with mild heterogeneous enhance-
ment in cases of soft tissue metastases. In bone metastases,
MRI showed avid heterogeneous enhancement. PET showed
nosigniﬁcantFDGuptakeforallmetastases.Theyconcluded
that MRI was the most useful imaging modality for bone
and soft tissue metastases. Similarly, there have been several4 Sarcoma
·+1(3)14 1
Figure 3: There is diﬀuse involvement of multiple vertebrae
including L5 seen throughout the spine on T1-weighted imaging
with both low and high signal.
Post T.L.Spine
Figure 4: The synchronous bone scan shows no signiﬁcant
abnormality in the spine compared to the MRI scan.
other case reports of spinal metastases diagnosed using MRI
which were undetectable on bone scintigraphy [7, 8, 17]. In
our series, all plain X-rays were negative, two out of four
bone scans were completely negative, and a PET scan was
also negative. In the largest series reported to date, 33 of 230
patients with MRCL were found to have developed spinal
metastases.Ninepatientshadbonescans,onlythreeofwhich
were positive in the spine and six patients had PET scans,
only two of which were positive [5] which is consistent with
our ﬁndings [5].
·+1(2) 1
Figure5:TheCTimagethroughL5showsnosigniﬁcantabnormal-
ity on bone windows in contrast to the MRI scan at the equivalent
level.
Bone scintigraphy is known to be more sensitive than
plain X-rays in the detection of bone metastases in solid
tumours. Scintigraphy may reveal bone metastases up to
18 months before they are apparent on radiography [18].
More than 50% of bone mineral content must be lost before
metastasis is evident on X-ray [19], and cells growing in the
marrow are less likely to be detected than those in the cortex
[20]. But in certain conditions such as myeloma or lesions
conﬁned to the marrow, bone scans have low sensitivity
[9]. It has been suggested that haematogenously seeded
intramedullary metastases produce marrow replacement
lesions detectable on MRI before any damage occurs in
the adjacent bone [21]. The high contrast between fat and
metastasis allows early demonstration of metastasis on MRI
assoonasmacroscopiclesionshavedevelopedinthemarrow
[22]. It is believed that isotope bone scans are negative in
myeloma because myeloma cells not only promote osteoclast
activity but also inhibit osteoblast diﬀerentiation [23]. In a
series of 74 patients with metastatic bone disease from a
number of diﬀerent primary sites, it was found that bone
scans were negative for all intramedullary lesions without
corticalinvolvementshownonMRimaging.Bonescanswere
frequently positive for transcortical (71.3%) or subcortical
involvement (33.8%). X-rays, CT, and bone scans mainly
assess the cortex whilst MRI can detect disease in the bone
marrow, where the early metastatic deposits occur. CT is
sensitiveindetectingsubtlecorticalinvasionbutlesssensitive
for medullary or bone marrow involvement [24]. In a
r e t r o s p e c t i v ec o m p a r i s o no fb o n es c a n sa n dM Ri m a g e si n
35 patients, a higher sensitivity for MRI in detecting bone
metastases was found compared to bone scans [25].
TechniquesforwholebodyboneimagingusingMRIhave
been investigated for the staging of patients with tumours,
such as Ewing sarcoma, with a high incidence of metastatic
bone disease [26]. MRI may produce fewer false positives
than PET, while it may be somewhat less sensitive. In theSarcoma 5
context of MRCL, whole body MRI could be proposed as
a staging investigation for the presence of metastatic bone
disease.
In conclusion, this is a retrospective review, with obvious
limitations regarding the ability to identify asymptomatic
patients with bone disease. In addition, we do not, as yet,
have a policy to screen patients with metastatic MRCL using
MRI. However, one may conclude that patients with this
diagnosiswhoexperiencebonepainespeciallyintheback,or
other unexplained symptoms, should be suspected of having
metastatic bone disease and for such patients MRI is the
investigation of choice.
Conﬂict of InterestStatement
None declared.
Acknowledgments
The authors wish to thank Omar Al-Muderis (data manager)
for his contribution to the Sarcoma Unit database and Andy
Prouse (data manager) for help with the Figures.
References
[ 1 ]F .M .E n z i n g e ra n dS .W .W e i s s ,Soft Tissue Tumors,M o s b y ,
Philadelphia, Pa, USA, 3ed edition, 1995.
[2] C. R. Antonescu, A. Elahi, J. H. Healey, et al., “Monoclonality
of multifocal myxoid liposarcoma: conﬁrmation by analysis of
TLS-CHOP or EWS-CHOP rearrangements,” Clinical Cancer
Research, vol. 6, no. 7, pp. 2788–2793, 2000.
[ 3 ]C .R .A n t o n e s c u ,S .J .T s c h e r n y a v s k y ,R .D e c u s e a r a ,e ta l . ,
“Prognostic impact of P53 status, tls-chop fusion transcript
structure, and histological grade in myxoid liposarcoma: a
molecular and clinicopathologic study of 82 cases,” Clinical
Cancer Research, vol. 7, no. 12, pp. 3977–3987, 2001.
[ 4 ]S .L .B l a i r ,J .J .L e w i s ,D .L e u n g ,J .W o o d r u ﬀ,a n dM .F .
Brennan, “Multifocal extremity sarcoma: an uncommon and
controversial entity,” Annals of Surgical Oncology, vol. 5, no. 1,
pp. 37–40, 1998.
[5] J.H.Schwab,P.J.Boland,C.Antonescu,M.H.Bilsky,andJ.H.
Healey, “Spinal metastases from myxoid liposarcoma warrant
screening with magnetic resonance imaging,” Cancer, vol. 110,
no. 8, pp. 1815–1822, 2007.
[6] T. Ishii, T. Ueda, A. Myoui, N. Tamai, N. Hosono, and H.
Yoshikawa, “Unusual skeletal metastases from myxoid liposar-
coma only detectable by MR imaging,” European Radiology,
vol. 13, 4, pp. L185–L191, 2003.
[7] R. Kirollos, G. Koutsoubelis, S. Ross, and S. A. Sarraj,
“An unusual case of spinal metastasis from a liposarcoma,”
European Journal of Surgical Oncology, vol. 22, no. 3, pp. 303–
305, 1996.
[ 8 ]J .S .K h u r a n a ,D .I .R o s e n t h a l ,A .E .R o s e n b e r g ,a n dH .J .
Mankin, “Skeletal metastases in liposarcoma detectable only
by magnetic resonance imaging,” Clinical Orthopaedics and
Related Research, no. 243, pp. 204–207, 1989.
[ 9 ]J .M .W o o l f e n d e n ,M .J .P i t t ,B .G .M .D u r i e ,a n dT .E .
Moon, “Comparison of bone scintigraphy and radiography in
multiple myeloma,” Radiology, vol. 134, no. 3, pp. 723–728,
1980.
[10] P. S. Reddy and M. V. Merrick, “Skeletal scintigraphy in
carcinoma of the kidney,” British Journal of Urology, vol. 55,
no. 2, pp. 171–173, 1983.
[ 1 1 ]J .J .P e t e r s o n ,M .J .K r a n s d o r f ,L .W .B a n c r o f t ,a n dM .I .
O’Connor, “Malignant fatty tumors: classiﬁcation, clinical
course, imaging appearance and treatment,” Skeletal Radiol-
ogy, vol. 32, no. 9, pp. 493–503, 2003.
[12] J. H. Schwab, P. Boland, T. Guo, et al., “Skeletal metastases in
myxoid liposarcoma: an unusual pattern of distant spread,”
Annals of Surgical Oncology, vol. 14, no. 4, pp. 1507–1514,
2007.
[13] E. Y. Cheng, D. S. Springﬁeld, and H. J. Mankin, “Frequent
incidence of extrapulmonary sites of initial metastasis in
patients with liposarcoma,” Cancer, vol. 75, no. 5, pp. 1120–
1127, 1995.
[14] S. H. Estourgie, G. P. Nielsen, and M. J. Ott, “Metastatic
patternsofextremitymyxoidliposarcomaandtheiroutcome,”
Journal of Surgical Oncology, vol. 80, no. 2, pp. 89–93, 2002.
[15] S. A. Hanna, Y. A. Qureshi, L. Bayliss, et al., “Late widespread
skeletal metastases from myxoid liposarcoma detected by MRI
only,” World Journal of Surgical Oncology, vol. 6, article 62,
2008.
[16] K. Sheah, H. A. Ouellette, M. Torriani, G. P. Nielsen, S. Katta-
puram, and M. A. Bredella, “Metastatic myxoid liposarcomas:
imaging and histopathologic ﬁndings,” Skeletal Radiology, vol.
37, no. 3, pp. 251–258, 2008.
[ 1 7 ]S .V .K a t t a p u r a m ,J .S .K h u r a n a ,J .A .S c o t t ,a n dG .Y .
El-Khoury, “Negative scintigraphy with positive magnetic
resonanceimaginginbonemetastases,”SkeletalRadiology,vol.
19, no. 2, pp. 113–116, 1990.
[18] J. J. Pagani and H. I. Libshitz, “Imaging bone metastases,”
RadiologicClinicsofNorthAmerica,vol.20,no.3,pp.545–560,
1982.
[19] G. A. Edelstyn, P. J. Gillespie, and F. S. Grebbell, “The radi-
ological demonstration of osseous metastases. experimental
observations,” Clinical Radiology, vol. 18, no. 2, pp. 158–162,
1967.
[20] Rankin, Radiology, Springer, London, UK, 1991.
[21] P.R.Algra,J.L.Bloem,H.Tissing,T.H.Falke,J.W.Arndt,and
L. J. Verboom, “Detection of vertebral metastases: comparison
between MR imaging and bone scintigraphy,” Radiographics,
vol. 11, no. 2, pp. 219–232, 1991.
[22] C. S. B. Galasko, “Skeletal metastases,” Clinical Orthopaedics
and Related Research, vol. 210, pp. 18–30, 1986.
[23] G. R. Mundy, L. G. Raisz, R. A. Cooper, G. P. Schechter, and
S. E. Salmon, “Evidence for the secretion of an osteoclast
stimulating factor in myeloma,” The New England Journal of
Medicine, vol. 291, no. 20, pp. 1041–1046, 1974.
[24] T. Taoka, N. A. Mayr, H. J. Lee, et al., “Factors inﬂuencing
visualization of vertebral metastases on MR imaging versus
bone scintigraphy,” American Journal of Roentgenology, vol.
176, no. 6, pp. 1525–1530, 2001.
[25] E. Gosﬁeld III, A. Alavi, and B. Kneeland, “Comparison of
radionuclide bone scans and magnetic resonance imaging in
detecting spinal metastases,” Journal of Nuclear Medicine, vol.
34, no. 12, pp. 2191–2198, 1993.
[26] H. E. Daldrup-Link, C. Franzius, T. M. Link, et al., “Whole-
body MR imaging for detection of bone metastases in children
and young adults: comparison with skeletal scintigraphy and
FDG PET,” American Journal of Roentgenology, vol. 177, no. 1,
pp. 229–236, 2001.